Can Mounjaro, Wegovy or Ozempic Kill You?

What today’s ‘GLP-1 deaths’ headlines really mean – and how a lifestyle-first, lowest-effective-dose approach changes the conversation

By Graham Phillips FRPharmS, The Pharmacist Who Gave Up Drugs

If you use Mounjaro, Wegovy or Ozempic, you may have seen today’s frightening headlines reporting deaths linked to GLP-1 medicines. Some reports now refer to more than 200 deaths. So should you be worried? Should you stop your injection? And, bluntly: could it kill you?

THE 30-SECOND ANSWER

Yes, GLP-1 and GIP/GLP-1 medicines can cause serious adverse effects and, very rarely, those complications can be fatal. But a death reported to the MHRA Yellow Card scheme is not the same thing as a death proven to have been caused by the drug. We cannot use Yellow Card totals to calculate your personal risk of dying. And in a large randomised trial of Wegovy in a high-risk population, semaglutide was associated with fewer deaths than placebo. The sensible response is neither panic nor complacency: use these medicines only when the likely benefit justifies the risk, with proper supervision and no more drug than you actually need.

What are today’s headlines actually saying?

The Times reported more than 100,000 suspected adverse reactions for tirzepatide (Mounjaro), around 44,000 for Wegovy and just over 3,000 for Saxenda. In terms of fatalities the Times  reported 153 suspected deaths across Mounjaro, Wegovy and Saxenda (98, 37 and 18 respectively) based on MHRA Yellow Card data. Other UK coverage published the following day in The Sun reported a higher total of 216 (120, 59 and 37 respectively). The reason for the discrepancy between the two reported extracts is not clear from the published articles.

Source: figures reported by The Times, 5-6 August 2026. These are suspected adverse-reaction/fatal-outcome reports, not adjudicated drug-caused deaths; a single patient may generate more than one reaction report.

‘Reported after taking it’ is not the same as ‘killed by it’

The Yellow Card scheme is one of the UK’s most important pharmacovigilance tools. Patients, relatives, healthcare professionals and pharmaceutical companies are encouraged to report a suspected adverse reaction even when they are not certain that the medicine caused it. That deliberately makes the system sensitive to possible safety signals. It also means it cannot, by itself, prove causation.

The MHRA is explicit: the existence of an adverse-reaction report does not necessarily mean that the medicine caused the event. The illness being treated, an underlying or previously undiagnosed condition, another medicine, or simple coincidence may be responsible. Reporting is also influenced by how widely a medicine is used and by publicity.

DON’T DO THIS !

‘Reported deaths divided by an estimate of UK GLP-1 users = my risk of dying.’ It looks scientific, but it is not. The numerator is not a count of proven drug-caused deaths; the denominator does not necessarily represent the same people, products, exposure period or duration of treatment. Yellow Card data are designed to find safety signals, not calculate an individual incidence of death.

But let’s not make the opposite mistake: serious risks are real

Saying that Yellow Card reports of harm do not prove causation must not be used to wave away genuine risks. These are biologically active medicines which cause well-recognised adverse reactions some of which are serious and can, albeit rarely, be fatal.

Acute pancreatitis

In January 2026 the UK medicines regulator (MHRA) strengthened warnings for GLP-1 and dual GIP/GLP-1 medicines after rare reports of severe, necrotising and fatal pancreatitis. Between 2007 and October 2025, the MHRA had received 1,296 Yellow Card reports of pancreatitis associated with this group of medicines; 24 were reported as necrotising pancreatitis and 19 had a fatal outcome. The MHRA describes the overall frequency of acute pancreatitis as uncommon.

Gallbladder disease, dehydration and kidney injury

Nausea, vomiting, diarrhoea and constipation are common. Usually they are unpleasant rather than dangerous, but persistent vomiting or diarrhoea can cause significant dehydration and kidney injury. Gallstones and gallbladder inflammation are also recognised risks. These are precisely the sorts of problems that should make us take slow dose upwards titration and follow-up seriously rather than treating side effects as proof that the drug is ‘working properly’

Anaesthesia and aspiration

GLP-1 medicines delay gastric emptying making you feel fuller for longer. The MHRA therefore warns that people undergoing general anaesthesia or deep sedation may retain stomach contents despite routine fasting, increasing the risk of pulmonary aspiration. Patients should tell the anaesthetic team that they are taking a GLP-1 or GIP/GLP-1 medicine and should not stop treatment on their own without discussing the plan with their clinical team.

RED FLAG – SEEK URGENT MEDICAL HELP

Severe, persistent abdominal pain – particularly pain that radiates through to the back, with or without nausea and vomiting – may indicate acute pancreatitis. Do not simply assume that severe abdominal pain is a ‘normal Mounjaro side effect’. The MHRA advises urgent medical assessment; if pancreatitis is suspected, treatment should be stopped and it should not be restarted if pancreatitis is confirmed.

The crucial question the headlines fail to ask: does treatment increase or decrease overall mortality?

This is where the story becomes more interesting. If a drug occasionally causes serious harm but prevents even more heart attacks, strokes and deaths, its overall benefit-risk balance may still be strongly positive in the right patient.

The SELECT trial randomised 17,604 adults aged 45 or over who were overweight or living with obesity, had established cardiovascular disease and did not have diabetes, to semaglutide 2.4 mg or placebo. Over a mean 3.3 years, 833 participants died. The hazard of death from any cause was 19% lower in the semaglutide group (hazard ratio 0.81; 95% CI 0.71-0.93).

That is powerful evidence against the simplistic claim that overall ‘GLP-1s kill people’. But it is equally important not to overclaim. SELECT studied a specific, relatively high-risk population. It does not prove a 19% mortality reduction for a healthy person taking semaglutide to lose a modest amount of weight, and it cannot simply be extrapolated to every GLP-1 including  tirzepatide.

Dose matters – and this changes how I think about GLP-1 treatment

There is a tendency in weight-loss medicine to treat the target dose as the destination: start low, titrate upwards and keep going until the maximum licensed dose or until side effects stop you. We believe that ink we should ask a completely different question: “what is the lowest dose that achieves the clinical objective for this individual?”

There is real evidence behind the principle that exposure matters, particularly for gastrointestinal adverse effects. For example the Mounjaro Summary of Product Characteristics describes the incidence of gastrointestinal disorders in pooled type 2 diabetes trials as increasing in   dose-dependent manner: 37.1% at 5 mg, 39.6% at 10 mg and 43.6% at 15 mg. Permanent discontinuation because of gastrointestinal events rose from 3.0% at 5 mg to 6.6% at 15 mg.

In the pooled weight-management trials, the overall proportion reporting a gastrointestinal disorder was similar across doses, but GI-related permanent discontinuation increased from 1.9% at 5 mg to 3.3% at 10 mg and 4.3% at 15 mg. With semaglutide, the Ozempic product information likewise shows modestly higher rates of several gastrointestinal effects as dose increases from 0.5 mg to 1 mg, and higher-dose trials show why gradual titration matters.

IMPORTANT QUALIFICATION

Dose-response is not universal. We lack evidence showing that a half-dose will halve the risk of pancreatitis, bowel complications or a fatal adverse event. The data isn’t present to reach  that conclusion. ‘Lowest effective dose’ is therefore a rational risk-minimisation and tolerability principle  but not a guarantee that low dose means zero risk.

What about ‘microdosing’?

Microdosing is not a formal licensed dosing category. The term is generally used for doses below, or dosing intervals longer than, the standard licensed maintenance schedules. The clinical-trial evidence for specific microdosing regimens is limited, so we cannot pretend that we have randomised evidence proving that a particular microdose prevents pancreatitis or other rare complications.

That does not make the underlying principle irrational however. Drug Treatments of all sorts  routinely use dose titration to balance benefits against adverse effects. Where a lower exposure provides sufficient appetite control and allows a person to make effective lifestyle changes, automatically escalating the dose simply because a higher dose exists makes little sense. Any non-standard dosing, however, needs to be an individual prescriber-led decision with the patient aware that it is outside the licensed regimen; patients should not improvise doses or alter injection devices themselves.

The ProLongevity approach: Lifestyle First. Medication Second.  Lowest Effective Dose.

This is where our philosophy differs from seeing weight-loss medications as the answer in themselves. Mounjaro and Wegovy can be extraordinarily useful tools – particularly when relentless hunger and ‘food noise’ are preventing someone from making changes they already understand. But reducing appetite is an opportunity, not the whole treatment.

We leverage that opportunity to build the things that improve metabolic health independently of GLP-based medications:

• Eat nutrient-dense food and prioritise adequate protein.
• Preserve and build muscle with resistance exercise.
• Improve sleep, movement and cardiorespiratory fitness.
• Address ultra-processed food, alcohol and other drivers of excess energy intake.
• Use medication when it adds meaningful benefit – and periodically reassess how much is actually required.

If those changes mean that satisfactory appetite control and metabolic improvement can be achieved with less medication, that can plausibly reduce dose-related adverse effects and may reduce drug expenditure. It can also reduce reliance on pharmacological appetite suppression. But ‘lifestyle first’ should not be sold as a guarantee that everyone can stop treatment without weight regain.

We know why that caution matters. In the STEP 1 extension, participants regained around two-thirds of the weight they had lost within a year of withdrawing semaglutide, on average. Tirzepatide withdrawal trials tell a similar story. For some people, obesity behaves as a chronic relapsing condition and long-term pharmacotherapy may remain appropriate. Sustainability therefore means building a health strategy that survives real life – whether that ultimately requires no drug, a lower dose, intermittent prescriber-supervised support, or ongoing licensed therapy.

THE PROLONGEVITY PRINCIPLE

The right person. The right medicine. The lowest effective exposure. Lifestyle doing as much of the heavy lifting as possible. Review rather than automatic escalation. This is not anti-medication; it is rational medication use.

Who worries us most?

Its not as straightforward as ‘anyone taking Mounjaro’. We’re more concerned about the person who:

• keeps increasing the dose despite significant nausea, vomiting or inability to eat and drink normally;
• dismisses severe or persistent abdominal pain as an expected side effect;
• is becoming dehydrated or has symptoms suggestive of kidney injury;
• loses weight rapidly without enough protein or resistance exercise to protect lean tissue;
• does not tell an anaesthetist or surgical team that they are taking a GLP-1 medicine;
• obtains pens from social media, unregulated sellers or other sources outside the legitimate medicines supply chain; or
• uses a powerful prescription medicine for cosmetic weight loss with little expected health benefit to offset the risk.

Should I stop Mounjaro or Wegovy because of today’s headlines?

No – not solely because of a newspaper headline. If the medicine was appropriately prescribed, you are tolerating it and it is producing worthwhile benefit, today’s Yellow Card figures do not suddenly change that into a dangerous treatment. Speak to your prescriber if the reports have changed how you feel about the balance of benefits and risks.

If, however, you have severe persistent abdominal pain, repeated vomiting, signs of significant dehydration, or another worrying new symptom, that is different: seek clinical advice promptly rather than waiting for the next routine review.

So: will Mounjaro, Wegovy or Ozempic kill me?

No honest clinician can promise that a medicine carries zero risk. Very rare fatal complications can occur. But the current headlines do not show that hundreds of people have been proven to have been killed by these drugs, and Yellow Card data cannot tell you your individual probability of dying.

For the right patient, the benefits can be substantial – and in high-cardiovascular-risk patients treated with semaglutide, randomised evidence actually shows a reduction in all-cause mortality. For someone with little to gain medically, the same treatment may have a much less attractive benefit-risk equation.

Our conclusion is therefore neither ‘GLP-1s are all dangerous’ nor ‘GLP-1s are safe’. It is nuanced: don’t use more medicine than you need, and don’t ask medicine to do the job that better food, movement, muscle and sleep can do for you.

Lifestyle First -> Medication When Useful -> Lowest Effective Dose -> Keep Building Health

References and further reading

1. MHRA Yellow Card interactive Drug Analysis Profile: tirzepatide
2. MHRA: strengthened warnings on acute pancreatitis, including necrotising and fatal cases 29 January 2026.
3. Mounjaro KwikPen – Summary of Product Characteristics Electronic Medicines Compendium.
4. Wegovy 2.4 mg – Summary of Product Characteristics Electronic Medicines Compendium.
5. Ozempic 0.5 mg – Summary of Product Characteristics Electronic Medicines Compendium.
6. Scirica BM et al. The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial J Am Coll Cardiol. 2024;84:1632-1642. doi:10.1016/j.jacc.2024.08.007.
7. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity N Engl J Med. 2022;387:205-216. doi:10.1056/NEJMoa2206038.
8. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension Diabetes Obes Metab. 2022;24:1553-1564.
9. MHRA: potential risk of pulmonary aspiration during general anaesthesia or deep sedation 28 January 2025.
10. The Times: More than 100 deaths after Mounjaro or Wegovy use reported 5-6 August 2026. Secondary reporting used only for the day-of-publication headline figures.